Big Pharma Fined $3.75 Billion in Fraud Penalties in Fiscal 2013

According to the U.S. Departments of Justice and Health and Human Services, these departments recovered $4.3 billion in criminal and civil fines in the 2013 fiscal year, which ended in September 2013.  This is a $100 million increase from the 2012 fiscal year.  The five-year total in fines has now reached $19.2 billion.  Pharma drugmakers [...]

March 3rd, 2014|Drug and Medical Device Litigation|Comments Off on Big Pharma Fined $3.75 Billion in Fraud Penalties in Fiscal 2013

Whistleblowers, Undercover Employees Wearing Wires Led To Johnson & Johnson’s Guilty Plea Involving Risperdal

As reported earlier, Johnson & Johnson will pay $2.2 billion due to its practices of improper marketing and failure to warn.  Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, admitted that it promoted Risperdal to health care providers for treatment of psychotic symptoms and associated behavioral disturbances exhibited by elderly, non-schizophrenic dementia patients. More facts [...]

November 12th, 2013|Drug and Medical Device Litigation|Comments Off on Whistleblowers, Undercover Employees Wearing Wires Led To Johnson & Johnson’s Guilty Plea Involving Risperdal

Big Pharma: Is Paying Big Fines More Profitable than Telling Doctors and Consumers the Truth in Marketing?

This week, Johnson & Johnson etched its name in the history books of another big pharma company that has been fined over billions of dollars due to a drug manufacturer practices of improper marketing and failure to warn.  Johnson & Johnson pled guilty to claims stemming from allegations that the giant pharmaceutical company knowingly marketed [...]

November 7th, 2013|Actos Diabetes Drug, Avandia Diabetes Drug, DePuy Hip Replacement, Drug and Medical Device Litigation, Fosamax Osteoporosis Drug, Lipitor, Transvaginal Mesh|Comments Off on Big Pharma: Is Paying Big Fines More Profitable than Telling Doctors and Consumers the Truth in Marketing?

Johnson & Johnson Pleads Guilty to Criminal Charges and is Fined $2.2 Billion for Improperly Marketing Risperdal

Janssen Pharmaceuticals, Inc. (JPI), a Johnson and Johnson company, has pled guilty to claims stemming from allegations that the giant pharmaceutical company knowingly marketed the anti-psychotic drug Risperdal for inappropriate uses and paid kickbacks to doctors and nursing homes in prescribing the drug.  JPI will plead guilty to one misdemeanor violation of the Food Drug [...]

November 5th, 2013|Drug and Medical Device Litigation|Comments Off on Johnson & Johnson Pleads Guilty to Criminal Charges and is Fined $2.2 Billion for Improperly Marketing Risperdal

Johnson & Johnson Recalls Another DePuy Orthopedic Product

Johnson & Johnson (J&J) is no stranger to controversy.  From being embroiled in massive litigation in DePuy ASR artificial hips, Pinnacle litigation, and in the transvaginal mesh litigation with its Ethicon Gynecare products to its multiple legal troubles and fines associated with the anti-psychotic drug Risperdal, some things do not change for J&J – they [...]

August 2nd, 2013|DePuy Hip Replacement, Drug and Medical Device Litigation, Transvaginal Mesh|Comments Off on Johnson & Johnson Recalls Another DePuy Orthopedic Product

Risperdal Continues to Boggle Down Johnson & Johnson

Trouble is no stranger to Johnson & Johnson.  Johnson and Johnson (J&J), embroiled in massive litigation in DePuy ASR artificial hips, and in transvaginal mesh litigation from its Ethicon Gynecare products, faces more legal issues from its anti-psychotic drug, Risperdal.  Currently, Johnson & Johnson is appealing a 1.2 billion dollar fine issued in an Arkansas [...]

June 24th, 2013|Uncategorized|Comments Off on Risperdal Continues to Boggle Down Johnson & Johnson

Risperdal adds to DePuy and Ethicon Troubles for J&J

Johnson and Johnson (J&J), already embroiled in massive litigation in DePuy ASR artificial hips, and in the trans vaginal mesh litigation from its Ethicon Gynecare products, faces another significant issue over its mounting legal troubles stemming from its antipsychotic drug Risperdal.  The drug was approved in 1993 for use in adults and was also later [...]

May 12th, 2013|DePuy Hip Replacement, Drug and Medical Device Litigation, Transvaginal Mesh|Comments Off on Risperdal adds to DePuy and Ethicon Troubles for J&J